GF Fund Management’s Allogene Therapeutics ALLO Stock Holding History

GF Fund Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.9K	Buy	7,431 +611	+9%	+$1.16K	﹤0.01%	532
2026 Q2	$14.2K	Buy	6,820 +1,773	+35%	+$3.89K	﹤0.01%	512
2026 Q1	$12.3K	Buy	5,047 +769	+18%	+$1.54K	﹤0.01%	542
2025 Q4	$5.86K	Sell	4,278 -496	-10%	-$654	﹤0.01%	618
2025 Q3	$5.92K	Sell	4,774 -594	-11%	-$708	﹤0.01%	601
2025 Q2	$6.07K	Hold	5,368	–	–	﹤0.01%	615
2025 Q1	$7.84K	Buy	5,368 +965	+22%	+$1.82K	﹤0.01%	589
2024 Q4	$9.38K	Buy	+4,403	New	+$10.9K	﹤0.01%	554

Other funds holding ALLO

Pfizer New York $164M AUM 53.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

GF Fund Management's ALLO Position: Q3 2026 in Review

GF Fund Management increased its Allogene Therapeutics (ALLO) stake by 9% in Q3 2026, buying an estimated $1.16K and bringing the position to 7,431 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #532.

GF Fund Management first reported a position in ALLO in Q4 2024 and has held it in 8 quarters since. The position peaked at $14.2K in Q2 2026. 105 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

GF Fund Management held 7,431 shares of Allogene Therapeutics worth $11.9K as of Q3 2026.
GF Fund Management bought 611 Allogene Therapeutics shares in Q3 2026, an estimated $1.16K.
Allogene Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #532 holding.
GF Fund Management first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 8 quarters since.
GF Fund Management's Allogene Therapeutics position peaked at $14.2K in Q2 2026.
105 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.